Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01648556Not ApplicableCompleted

Research of Predictive Factors to Immune Thrombopenic Purpura

Role: collaborator

NCT06585020Phase 2Recruiting

Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

Role: collaborator

NCT04469491Phase 2Active Not Recruiting

Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study

Role: collaborator

NCT04748796Phase 3Recruiting

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

Role: collaborator

All 4 trials loaded